Endoscopy 2008; 40(12): 1041-1047
DOI: 10.1055/s-0028-1103410
Total Barrett Eradication review section

© Georg Thieme Verlag KG Stuttgart · New York

The future of endoscopic treatment of early Barrett neoplasia: The endoscopist’s view

G.  W.  Falk1
  • 1Department of Gastroenterology and Hepatology, Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio, USA
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Dezember 2008 (online)

Introduction

The field of Barrett’s esophagus ablation has come a long way since the original pioneering work of Brandt and Berenson in the early 1990s [1] [2]. In fact, ablation is now viewed as a legitimate first-line treatment option for healthy patients with high grade dysplasia and early adenocarcinoma, based on studies performed to date. Furthermore, the notion of complete ablation of Barrett’s esophagus has moved from concept to reality. That being said, many questions about endoscopic ablation of Barrett’s esophagus remain unanswered. This section will try to address the following issues regarding the endoscopic ablation of Barrett’s esophagus:

Where have we been? Where are we now? What are currently unresolved issues in endoscopic ablation? What are potential solutions for these issues?

References

  • 1 Brandt L J, Kauvar D R. Laser-induced transient regression of Barrett’s epithelium.  Gastrointest Endosc. 1992;  38 619-622
  • 2 Berenson M M, Johnson T D, Markowitz N R. et al . Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium.  Gastroenterology. 1993;  104 1686-1691
  • 3 Garewal H, Ramsey L, Sharma P. et al . Biomarker studies in reversed Barrett’s esophagus.  Am J Gastroenterol. 1999;  94 2829-2833
  • 4 Ackroyd R, Brown N J, Davis M F. et al . Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial.  Gut. 2000;  47 612-617
  • 5 Bergman J J, Fockens P. Ablating Barrett’s metaplastic epithelium: are the techniques ready for clinical use?.  Gut. 2006;  55 1222-1223
  • 6 Schoenfeld P, Scheiman J. An evidence-based approach to studies of gastrointestinal therapies.  Clin Gastroenterol Hepatol. 2003;  1 57-63
  • 7 Spechler S J. Thermal ablation of Barrett’s esophagus: a heated debate.  Am J Gastroenterol. 2006;  101 1770-1772
  • 8 Van Laethem J L, Peny M O. et al . Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus.  Gut. 2000;  46 574-577
  • 9 Shand A, Dallal H, Palmer K. et al . Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation.  Gut. 2001;  48 580-581
  • 10 Mino-Kenudson M, Ban S, Ohana M. et al . Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy.  Am J Surg Pathol. 2007;  31 403-409
  • 11 Krishnadath K K, Wang K K, Taniguchi K. et al . Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy.  Gastroenterology. 2000;  119 624-630
  • 12 Hage M, Siersema P D, Vissers K J. et al . Molecular evaluation of ablative therapy of Barrett’s oesophagus.  J Pathol. 2005;  205 57-64
  • 13 Hage M, Siersema P D, Vissers K J. et al . Genomic analysis of Barrett’s esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.  Int J Cancer. 2006;  118 155-160
  • 14 Dvorak K, Ramsey L, Payne C M. et al . Abnormal expression of biomarkers in incompletely ablated Barrett’s esophagus.  Ann Surg. 2006;  244 1031-1036
  • 15 Pech O, Nagy C D, Gossner L. et al . Photodynamic therapy of human Barrett’s cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice.  Eur J Gastroenterol Hepatol. 2002;  14 657-662
  • 16 Johnston C M, Schoenfeld L P, Mysore J V. et al . Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus.  Gastrointest Endosc. 1999;  50 86-92
  • 17 Pasricha P J, Hill S, Wadwa K S. et al . Endoscopic cryotherapy: experimental results and first clinical use.  Gastrointest Endosc. 1999;  49 627-631
  • 18 Johnston M H. Cryotherapy and other newer techniques.  Gastrointest Endosc Clin N Am. 2003;  13 491-504
  • 19 Prasad G A, Wang K K, Buttar N S. et al . Long term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus.  Gastroenterology. 2007;  132 1226-1233
  • 20 Das A, Singh V, Fleischer D E. et al . A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data.  Am J Gastroenterol. 2008;  103 1340-1345
  • 21 Kelty C J, Ackroyd R, Brown N J. et al . Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.  Aliment Pharmacol Ther. 2004;  20 1289-1296
  • 22 Dulai G S, Jensen D M, Cortina G. et al . Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus.  Gastrointest Endosc. 2005;  61 232-240
  • 23 Sharma P, Wani S, Weston A P. et al . A randomised controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.  Gut. 2006;  55 1233-1239
  • 24 Overholt B F, Lightdale C J, Wang K K. et al . Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial.  Gastrointest Endosc. 2005;  62 488-498
  • 25 Shaheen N J, Sharma P, Overholt B F. et al . A randomized, multicenter, sham-controlled trial of radiofrequency ablation for subjects with Barrett’s esophagus containing dysplasia: interim results of the AIM dysplasia trial.  Gastroenterology. 2008;  134 A37
  • 26 Overholt B F, Wang K K, Burdick J S. et al . Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia.  Gastrointest Endosc. 2007;  66 460-468
  • 27 Ganz R A, Utley D S, Stern R A. et al . Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus.  Gastrointest Endosc. 2004;  60 1002-1010
  • 28 Dunkin B J, Martinez J, Bejarano P A. et al . Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device.  Surg Endosc. 2006;  20 125-130
  • 29 Sharma V K, Wang K K, Overholt B F. et al . Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients.  Gastrointest Endosc. 2007;  65 185-195
  • 30 Fleischer D E, Overholt B F, Sharma V K. et al . Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up.  Gastrointest Endosc. 2008;  Jun 16 [Epub ahead of print]
  • 31 Ell C, May A, Pech O. et al . Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).  Gastrointest Endosc. 2007;  65 3-10
  • 32 Wang K K, Sampliner R E. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2008;  103 788-797
  • 33 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system.  Endoscopy. 2008;  40 370-379
  • 34 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients.  Endoscopy. 2008;  40 359-369
  • 35 Johnston M H, Eastone J A, Horwhat J D. et al . Cryoablation of Barrett’s esophagus: a pilot study.  Gastrointest Endosc. 2005;  62 842-848
  • 36 Dumot J A, Vargo J J, Zuccaro G. et al . Results of cryospray ablation for esophageal high grade dysplasia (HGD) and intramucosal cancer (IMCA) in high risk non-surgical patients.  Gastrointest Endosc. 2008;  67 AB176
  • 37 Seewald S, Akaraviputh T, Seitz U. et al . Circumferential EMR and complete removal of Barrett’s epithelium: a new approach to management of Barrett’s esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma.  Gastrointest Endosc. 2003;  57 854-859
  • 38 Giovannini M, Bories E, Pesenti C. et al . Circumferential endoscopic mucosal resection in Barrett’s esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients.  Endoscopy. 2004;  36 782-787
  • 39 Peters F P, Kara M A, Rosmolen W D. et al . Stepwise radical endoscopic resection is effective for complete removal of Barrett’s esophagus with early neoplasia: a prospective study.  Am J Gastroenterol. 2006;  101 1449-1457
  • 40 Larghi A, Lightdale C J, Ross A S. et al . Long term follow-up of complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.  Endoscopy. 2007;  39 1086-1091
  • 41 Yoshinaga S, Gotoda T, Kusano C. et al . Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction.  Gastrointest Endosc. 2008;  67 202-209
  • 42 Spechler S J, Sharma P, Traxler B. et al . Gastric and esophageal pH in patients with Barrett’s esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.  Am J Gastroenterol. 2006;  101 1964-1971
  • 43 Sampliner R E, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 270-272
  • 44 Kovacs B J, Chen Y K, Lewis T D. et al . Successful reversal of Barrett’s esophagus with multipolar electrocoagulation despite inadequate acid suppression.  Gastrointest Endosc. 1999;  49 547-553
  • 45 Hornick J L, Mino-Kenudson M, Lauwers G Y. et al . Buried Barrett’s epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities.  Am J Gastroenterol. 2008;  103 38-47
  • 46 Ackroyd R, Brown N J, Stephenson T J. et al . Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed?.  J Clin Pathol. 1999;  52 509-512
  • 47 Leedham S J, Preston S L, McDonald S A. et al . Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus.  Gut. 2008;  57 1041-1048
  • 48 Weston A P, Sharma P, Banerjee S. et al . Visible endoscopic and histologic changes in the cardia, before and after complete Barrett’s esophagus ablation.  Gastrointest Endosc. 2005;  61 515-521
  • 49 Sampliner R E, Camargo E, Prasad A R. Association of ablation of Barrett’s esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia.  Dis Esophagus. 2006;  19 277-279
  • 50 Fass R, Garewal H S, Hayden C W. et al . Preferential repair by squamous epithelium of thermal induced injury to the proximal stomach in patients undergoing ablation of Barrett’s esophagus.  Gastrointest Endosc. 2001;  53 711-716
  • 51 Fennerty M B, Corless C L, Sheppard B. et al . Pathological documentation of complete elimination of Barrett’s metaplasia following endoscopic multipolar electrocoagulation therapy.  Gut. 2001;  49 142-144
  • 52 Prasad G A, Wang K K, Halling K C. et al . Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus.  Gastroenterology. 2008;  135 370-379

G. W. FalkMD MS 

Department of Gastroenterology and Hepatology
Desk A-31
Cleveland Clinic

9500 Euclid Avenue, Cleveland
Ohio 44195, USA

Fax: 01-216-4446302

eMail: falkg@ccf.org